{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:18:29Z","timestamp":1785575909621,"version":"3.56.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD), and as the disease progresses SHPT is associated with systemic consequences, termed CKD-mineral and bone disorder. Currently, cinacalcet is indicated for the treatment of SHPT; however, cinacalcet is associated with upper gastrointestinal adverse events. Evocalcet has been developed to address these issues, but the long-term safety and efficacy of evocalcet need to be evaluated. To more accurately reflect clinical practice, this phase 3, multicenter, open-label study was specifically designed without a cinacalcet washout period, and focused on those patients who switched from cinacalcet to evocalcet. A total of 137 SHPT patients undergoing hemodialysis were enrolled, of whom 113 switched from cinacalcet to evocalcet. The most frequent type of adverse drug reaction was decreased adjusted calcium. The incidence of gastrointestinal-related adverse events did not increase in a dose-dependent manner as the dose of evocalcet was increased. The percentage of patients achieving the target intact parathyroid hormone concentration increased from 40.9% to 72.3% with 52-week treatment. The corrected serum calcium and phosphorus levels remained largely unchanged throughout the study. The long-term safety and efficacy of evocalcet was confirmed using a clinically relevant intra-subject dose-adjustment strategy in SHPT patients undergoing hemodialysis.<\/jats:p>","DOI":"10.1038\/s41598-019-42017-z","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T06:04:03Z","timestamp":1555999443000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis"],"prefix":"10.1038","volume":"9","author":[{"given":"Keitaro","family":"Yokoyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryutaro","family":"Shimazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of Evocalcet Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazue","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanori","family":"Azekura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotake","family":"Kasuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Tomiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeaki","family":"Shinzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Iwashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nagaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatomo","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,23]]},"reference":[{"key":"42017_CR1","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1159\/000156717","volume":"29","author":"T Shigematsu","year":"2009","unstructured":"Shigematsu, T. et al. Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism. Am. J. Nephrol. 29, 230\u2013236 (2009).","journal-title":"Am. J. Nephrol."},{"key":"42017_CR2","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2215\/CJN.06040710","volume":"6","author":"J Cunningham","year":"2011","unstructured":"Cunningham, J., Locatelli, F. & Rodriguez, M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. CJASN. 6, 913\u2013921 (2011).","journal-title":"CJASN."},{"key":"42017_CR3","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/ki.2015.72","volume":"88","author":"H Komaba","year":"2015","unstructured":"Komaba, H. et al. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 88, 350\u2013359 (2015).","journal-title":"Kidney Int."},{"key":"42017_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/sdi.12357","volume":"28","author":"M Rodr\u00edguez","year":"2015","unstructured":"Rodr\u00edguez, M. et al. The use of calcimimetics for the treatment of secondary hyperparathyroidism: a 10 year evidence review. Semin. Dial. 28, 497\u2013507 (2015).","journal-title":"Semin. Dial."},{"key":"42017_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1744-9987.2006.00389.x","volume":"10","author":"H Ogata","year":"2006","unstructured":"Ogata, H., Koiwa, F., Ito, H. & Kinugasa, E. Therapeutic strategies for secondary hyperparathyroidism in dialysis patients. Ther. Apher. Dial. 10, 355\u2013363 (2006).","journal-title":"Ther. Apher. Dial."},{"key":"42017_CR6","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1111\/j.1744-9987.2005.00310.x","volume":"9","author":"J Cunningham","year":"2005","unstructured":"Cunningham, J. Management of secondary hyperparathyroidism. Ther. Apher. Dial. 9, S35\u2013S40 (2005).","journal-title":"Ther. Apher. Dial."},{"key":"42017_CR7","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"The EVOLVE Trial Investigators","year":"2012","unstructured":"The EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N. Engl. J. Med. 367, 2482\u20132494 (2012).","journal-title":"N. Engl. J. Med."},{"key":"42017_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/srep19612","volume":"6","author":"T Akizawa","year":"2016","unstructured":"Akizawa, T. et al. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Sci. Rep. 6, 19612, https:\/\/doi.org\/10.1038\/srep19612 (2016).","journal-title":"Sci. Rep."},{"key":"42017_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2016.19468","volume":"317","author":"GA Block","year":"2017","unstructured":"Block, G. A. et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA. 317, 156\u2013164 (2017).","journal-title":"JAMA."},{"key":"42017_CR10","first-page":"567","volume":"27","author":"N Hamano","year":"2017","unstructured":"Hamano, N. & Fukagawa, M. Parenteral calcimimetics for the treatment of secondary hyperparathyroidism. Clin. Calcium. 27, 567\u2013572 (2017).","journal-title":"Clin. Calcium."},{"key":"42017_CR11","doi-asserted-by":"publisher","first-page":"e0195316","DOI":"10.1371\/journal.pone.0195316","volume":"13","author":"T Kawata","year":"2018","unstructured":"Kawata, T. et al. A novel calcimimetic agent, evocalcet (MT-4580\/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. PLoS One. 13, e0195316, https:\/\/doi.org\/10.1371\/journal.pone.0195316 (2018).","journal-title":"PLoS One."},{"key":"42017_CR12","first-page":"101","volume":"10","author":"T Shigematsu","year":"2018","unstructured":"Shigematsu, T., Shimazaki, R., Fukagawa, M. & Akizawa, T. Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan. Clin. Pharmacol. 10, 101\u2013111 (2018).","journal-title":"Clin. Pharmacol."},{"issue":"2","key":"42017_CR13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s10157-018-1635-6","volume":"23","author":"Takashi Shigematsu","year":"2018","unstructured":"Shigematsu, T., Shimazaki, R., Fukagawa, M., Akizawa, T. & Evocalcet Study Group. Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients. Clin. Exp. Nephrol. https:\/\/doi.org\/10.1007\/s10157-018-1635-6 [Epub ahead of print] (2018).","journal-title":"Clinical and Experimental Nephrology"},{"key":"42017_CR14","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.kint.2018.05.013","volume":"94","author":"M Fukagawa","year":"2018","unstructured":"Fukagawa, M., Shimazaki, R., Akizawa, T. & Evocalcet study group. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 94, 818\u2013825 (2018).","journal-title":"Kidney Int."},{"key":"42017_CR15","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1744-9987.2008.00648.x","volume":"12","author":"Guideline Working Group, Japanese Society for Dialysis Therapy","year":"2008","unstructured":"Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperthyroidism in chronic dialysis patients. Ther. Apher. Dial. 12, 514\u2013525 (2008).","journal-title":"Ther. Apher. Dial."},{"key":"42017_CR16","unstructured":"International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use. The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions, http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E1\/Step4\/E1_Guideline.pdf last accessed 15 September 2017 (1994)."},{"key":"42017_CR17","doi-asserted-by":"publisher","first-page":"e0204896","DOI":"10.1371\/journal.pone.0204896","volume":"13","author":"T Akizawa","year":"2018","unstructured":"Akizawa, T., Shimazaki, R., Fukagawa, M. & Evocalcet Study Group. Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study. PLoS One. 13, e0204896 (2018).","journal-title":"PLoS One."},{"key":"42017_CR18","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1744-9987.2007.00523.x","volume":"11","author":"Japanese Society for Dialysis Therapy","year":"2007","unstructured":"Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan (as of 31 December 2005). Ther. Apher. Dial. 11, 411\u2013441 (2007).","journal-title":"Ther. Apher. Dial."},{"key":"42017_CR19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/jama.2016.19456","volume":"317","author":"GA Block","year":"2017","unstructured":"Block, G. A. et al. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. JAMA. 317, 146\u2013155 (2017).","journal-title":"JAMA."},{"key":"42017_CR20","first-page":"1723","volume":"32","author":"M Fukagawa","year":"2017","unstructured":"Fukagawa, M. et al. A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163\/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol. Dial. Transplant. 32, 1723\u20131730 (2017).","journal-title":"Nephrol. Dial. Transplant."},{"key":"42017_CR21","doi-asserted-by":"publisher","first-page":"679","DOI":"10.2147\/TCRM.S108490","volume":"13","author":"M Cozzolino","year":"2017","unstructured":"Cozzolino, M. et al. Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide. Ther. Clin. Risk Manag. 13, 679\u2013689 (2017).","journal-title":"Ther. Clin. Risk Manag."},{"key":"42017_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5414\/CN108974","volume":"88","author":"K Yokoyama","year":"2017","unstructured":"Yokoyama, K. et al. A 12-week dose-escalating study of etelcalcetide (ONO-5163\/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients. Clin. Nephrol. 88, 68\u201378 (2017).","journal-title":"Clin. Nephrol."},{"key":"42017_CR23","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/14656566.2017.1303482","volume":"18","author":"N Hamano","year":"2017","unstructured":"Hamano, N., Komaba, H. & Fukagawa, M. Etelcalcetide for the treatment of secondary hyperparathyroidism. Expert Opin. Pharmacother. 18, 529\u2013534 (2017).","journal-title":"Expert Opin. Pharmacother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42017-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42017-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42017-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T03:56:32Z","timestamp":1671249392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42017-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,23]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["42017"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-42017-z","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735609032.793577519","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,23]]},"assertion":[{"value":"17 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study and preparation of the manuscript was sponsored by Kyowa Hakko Kirin Co., Ltd. K.Y. received consulting fees and lecture fees from Kyowa Hakko Kirin Co., Ltd., Ono Pharmaceutical Co., Ltd. and Torii Pharmaceutical Co., Ltd. M.F. has received consulting fees from Kyowa Hakko Kirin Co., Ltd. and Ono Pharmaceutical Co., Ltd., and lecture fees from Kyowa Hakko Kirin Co., Ltd., Bayer Yakuhin, Ltd., Torii Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd., and grants from Kyowa Hakko Kirin Co., Ltd. and Bayer Yakuhin, Ltd. T.A. has received consulting fees from Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc., Bayer Yakuhin, Ltd., Fuso Pharmaceutical Industries, Ltd., Japan Tobacco Inc., Ono Pharmaceutical Co., Ltd. and NIPRO Industry, and lecture fees from Kyowa Hakko Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Kissei Pharmaceutical Co., Ltd., Torii Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd. R.S. is employed by Kyowa Hakko Kirin Co., Ltd., which funded this research.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"6410"}}